arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Passage BIO, Inc.

PASG
$3.51 ▲ +0.02 (+0.57%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
31 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Passage BIO, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $11.3M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -146.7% ↘
FCF / Share $-2.86 ↗
Trailing P/E —
Price / Book 2.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-7.82M
↑ +16.7% —
FCF / Share Free cash flow per share
$-2.86
↑ +29.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
1
Cash Quality →
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters